ArticleNeurochemical research2025
Ulinastatin Attenuates Lipopolysaccharide-Induced Microglia Activation and Cognitive Deficits Via a MAPKs/JAK-STATs Dependent Manner.
Article in Neurochemical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Neurodegenerative diseases are age-associated disorders characterized by distinctive pathological features. Microglia are essential for brain development and function. Modulating microglial activation in neurodegenerative diseases may provide novel therapeutic strategies. Ulinastatin (UTI), an intrinsic serine protease inhibitor, is widely used to treat acute inflammatory disorders. Although the anti-inflammatory effects of UTI have been studied, the mechanisms by which it affects microglial activation remain incompletely understood. In this study, we investigated the effects of UTI on lipopolysaccharide (LPS)-induced microglial activation in both rats and BV2 mouse microglial cells, with a focus on the MAPK and JAK-STAT signaling pathways. We employed Morris water maze, ELISA, MTT assay, immunohistochemistry, immunofluorescence, and western blotting to evaluate the impact of UTI. Our results showed that LPS induced microglial activation via MAPK and JAK-STAT signaling, resulting in elevated TNF-α and IL-1β expression and spatial learning deficits in rats. UTI treatment suppressed LPS-induced microglial activation by modulating these pathways, reduced pro-inflammatory cytokine production, and attenuated spatial memory impairment. Notably, our findings provide new evidence that UTI exerts anti-inflammatory and neuroprotective effects by targeting MAPK/JAK-STAT-mediated microglial activation, suggesting its potential as a therapeutic agent for neuroinflammatory and neurodegenerative diseases.
Indexed as
Identifiers
41236598What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.